LDCT: technical notes
=====================

Even if low-dose computed tomography (LDCT) can be acquired with single-slice spiral computed tomography (CT)^\[^[@B3]^\]^, currently the use of multidetector row CT (MDCT) scanners is recommended. The rationale for using MDCT scanners is that most of the nodules detected on screening are small and require optimal spatial resolution for computer-aided detection (CAD) and nodule volume assessment^\[^[@B4]^\]^.

According to the National Lung Cancer Screening Trial (NLST) and International Early Lung Cancer Action Program (I-ELCAP), no less than 4-detector MDCT scanners are recommended for LDCT, to ensure that the chest can be scanned in a single breath-hold and to achieve good spatial resolution^\[^[@B5]^,^[@B6]^\]^.

Due to a high contrast resolution between air and lung nodules, LDCT enables a low radiation dose while maintaining good diagnostic quality. There is no consensus on which level of dose is considered a low dose and the factors affecting dose in CT are different, such as tube voltage (kVp, kilovolt peak), tube current (mA, milliampere) and tube speed rotation (s, second).

Various kVp and mAs values have been used in MDCT lung cancer screening programs^\[^[@B2]^\]^, with different estimated effective doses. A recent study, aimed at determining the distribution of effective dose associated with a single LDCT examination, concluded that acceptable CT screening can be accomplished at an overall average effective dose of approximately 2 mSv^\[^[@B9]^\]^).

A few recent lung cancer screening (LCS) trials have optimized the dose delivered based on the patient's weight; a comparative CT scan and reconstruction parameters of the largest LCS trials are summarized in [Table 1](#T1){ref-type="table"}. Table 1CT scanning and reconstruction parameters in some recent LCS trialsStudyDetectorsVoltage (kVp)Tube current (mA)PitchRotation time (s)Effective dose (mSv)Slice thickness (mm)Reconstruction interval (mm)I-ELCAP≥4≤120≤401.50.51--21.251.25NLST≥4120--140[^a^](#TF1){ref-type="table-fn"}40--80[^a^](#TF1){ref-type="table-fn"}NANA1.51.0--3.21.0--2.5UKLS\>1690 (\<50 kg)--[^b^](#TF2){ref-type="table-fn"}0.9--1.1NA\<2NANA120 (50--80 kg)140 (\>80 kg)NELSON16100 (\<60 kg)201.5NA\<210.7120 (60--80 kg)140 (\>80 kg)[^1][^2][^3]

Recently, CT manufacturers have introduced iterative reconstruction (e.g. adaptive statistical iterative reconstruction (ASIR), iDose, model-based iterative reconstruction (MBIR), etc.) instead of filtered back projection (FBP). The advantage of iterative algorithms is the noise reduction while spatial resolution, CT number accuracy and linearity are preserved. Unfortunately, no extensive data on the use of iterative reconstruction-based algorithms with LDCT are available and further studies are needed to assess the usefulness of this technique.

The collimation of LDCT should be set with the purpose of achieving thin-section reconstruction images, which allow the use of CAD and an optimal volumetric analysis. Therefore, reconstructed slice thickness, at least equal to or lower than 1.5 mm, should be used^\[^[@B2]^\]^. It is advisable to set the section interval lower than the slice thickness in order to reduce partial volume artifacts. This is critical for accurate nodule volume assessment.

The reconstruction kernel can affect the volume measurement of pulmonary nodules from LDCT examinations. In a previous study, the repeatability of volume measurements of pulmonary nodules obtained at 1-mm section thickness combined with a soft kernel was almost twice as good as the reconstruction obtained with a 2-mm section thickness combined with a soft kernel, and almost 4 times better than those obtained at 2-mm section thickness combined with a sharp kernel^\[^[@B10]^\]^.

LDCT: reading methods and nodule detection
==========================================

Pulmonary nodules
-----------------

The target of LDCT for screening purposes is the non-calcified pulmonary nodule. Lung nodules can be distinguished in solid nodules and subsolid nodules^\[^[@B11]^\]^. Subsolid nodules can be further classified as non-solid nodules and part-solid nodules ([Fig. 1](#F1){ref-type="fig"}). This classification is significant because different nodules require different approaches for their detection, measurement and management. Figure 1(a) Transverse unenhanced low-dose CT scan of a 63-year-old man shows a non-solid nodule in the upper left lobe (arrow). (b) Transverse unenhanced low-dose CT scan of a 66-year-old woman shows a part-solid nodule in the lower left lobe (arrow). (c) Transverse unenhanced low-dose CT scan of a 58-year-old man shows a solid nodule in the upper right lobe (arrow). All 3 nodules were surgically removed and were found to be adenocarcinoma of the lung.

Solid and subsolid nodules have different growth rates and subsolid nodules have a higher probability of malignancy. Li et al.^\[^[@B12]^\]^ compared malignant and benign nodules in an LCS study and found that the prevalence of malignancy was 59% for non-solid nodules, 48% for part-solid nodules and 11% for solid nodules. In the Early Lung Cancer Action Project^\[^[@B11]^\]^, 34% (15/44) of subsolid nodules detected at baseline were malignant, whereas malignancy rates for part-solid and non-solid nodules were 63% (10/16) and 18% (5/28), respectively, compared with only 7% for solid nodules.

Even if non-solid nodules are more likely to be malignant, their growth rate tends to be considerably slower than solid lesions^\[^[@B13]^,^[@B14]^\]^ with substantial implication for their follow-up interval and management ([Fig. 2](#F2){ref-type="fig"}). Conversely, solid and part-solid nodules when malignant are more likely to be invasive and faster growing cancers.

Subsolid nodules are mainly atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA). AIS and MIA are terms introduced by the new classification of lung adenocarcinoma^\[^[@B12]^\]^ (formerly known as bronchioloalveolar carcinoma (BAC)) and 5-year disease-free survival can approach 100% if surgically resected^\[^[@B2]^\]^. Figure 2Transverse unenhanced low-dose CT scans show a slow-growing pulmonary nodule of the lower right lobe in a 61-year-old man. In 2012, the nodule was surgically removed and was found to be adenocarcinoma of the lung. The nodule measured 5.5 mm in 2007 (a), 8.5 mm in 2009 (b) and 11 mm in 2012 (c).

Nodule detection
----------------

False-negative diagnosis due to perceptual error is a common problem in lung cancer diagnosis^\[^[@B15]^\]^. The performance of radiologists in nodule detection can be influenced by several factors such as CT parameters, reader experience and nodule location^\[^[@B18]^,^[@B19]^\]^. If the application of thin-slice MDCT raises the reader's sensitivity for lung nodule detection^\[^[@B20]^\]^, the detection rate is also affected by its location. Naidich et al.^\[^[@B18]^\]^ showed that perihilar lung nodules were detected with a sensitivity of 36.7% versus 73.9% of peripherally located nodules. They also noted that vessel-attached nodules were detected with a significantly low sensitivity (32.5%).

To improve the radiologist's detection rate, a double reading technique and CAD systems have been proposed for LDCT. Double reading significantly improved the detection rate of pulmonary nodules. Wormanns et al.^\[^[@B21]^\]^ showed that the average sensitivity for detection of 390 nodules (size 3.9 ± 3.2 mm) for single readers increased from 64% to 79% using double reading. However, a recent study^\[^[@B22]^\]^ showed that double reading in LCS did not increase the cancer detection rate but led to the detection of 19% more nodules.

The use of a CAD system can be of help for the detection of small pulmonary nodules. Rubin^\[^[@B23]^\]^ showed that the mean sensitivity for single reading, double reading and reader using CAD was 50%, 63% and 76%, respectively. Armato et al.^\[^[@B16]^\]^ showed that CAD detected 78% of missed lung nodules and found 93% of nodules undiagnosed due to interpretation error. The accuracy of CAD for nodule detection increases with thinner reconstruction images and with overlapping reconstructed sections^\[^[@B24]^\]^, even if this causes an increasing number of false-positive results. The use of CAD system seems to be poorly affected by dose level. Lee et al.^\[^[@B25]^\]^ used 4 different tube currents (32, 16, 8 and 4 mAs) in 25 volunteers and found no significant differences in nodule detection between the scans with 8 mAs and those with 32 mAs. The reader's experience using CAD systems is also significant. In one study performing receiver operating curve (ROC) analyses of single and combined reader performances involving experienced (6--8 years experience) and inexperienced radiologists (6 months experience), the overall performance of an experienced radiologist with CAD assistance was significantly better than that of an inexperienced radiologist using CAD as second reader^\[^[@B26]^\]^.

The detection rate of pulmonary nodules can also be improved using maximum intensity projection (MIP). Bastarrika et al.^\[^[@B27]^\]^ showed that non-overlapping 10-mm-thick axial MIP reconstructions in an LCS study enabled more accurate detection of pulmonary nodules in comparison with 1.25-mm conventional axial images. Jankowski et al.^\[^[@B28]^\]^ evaluated the diagnostic benefits of MIP and a CAD system for pulmonary nodules detection compared with 1-mm LDCT images. The investigators found that MIP and CAD reduced the number of overlooked nodules compared with LDCT and that the MIP was more sensitive than the CAD. Multiplanar reconstructions images (MPR) were shown to be a sensitive technique in lung nodule detection^\[^[@B29]^,^[@B30]^\]^.

However, there is no consensus on which technique should be used to read low-dose CT images and further investigations are needed to assess the optimal method to improve the detection rate of pulmonary nodules.

Beyond pulmonary nodules
------------------------

Chest LDCT can provide additional information, including cardiovascular disease and chronic obstructive pulmonary disease (COPD). Some studies support the idea that coronary artery calcium (CAC) scoring as part of ungated LDCT can be useful to assess the risk of cardiovascular disease^\[^[@B31]^,^[@B32]^\]^. In a study to compare CAC and thoracic aorta calcium (TAC) as independent predictors of all-cause mortality and cardiovascular events in an LCS trial, the investigators concluded that CAC is a stronger predictor than TAC for all-cause mortality, cardiovascular and coronary events^\[^[@B33]^\]^. LDCT was also shown to be a reliable technique for the quantification and evolution of emphysema^\[^[@B34]^\]^. The accuracy of COPD diagnosis with LDCT has been recently evaluated^\[^[@B37]^\]^; inspiratory and expiratory LDCT scans can identify participants with COPD with a sensitivity and specificity of 63% and 88%, respectively. A comprehensive evaluation of LDCT should not be limited to the lung parenchyma. A recent study shown that extrapulmonary malignancy in an LCS trial is diagnosed with a frequency of 1 case per 200 individuals screened^\[^[@B38]^\]^.

LDCT: nodule measurement
========================

Size and growth are the most important parameters in the management of pulmonary nodules detected on screening. Therefore, it seems essential to use an accurate and reproducible method for reliable measurement of pulmonary nodules. Manual and volumetric methods are currently used to assess nodule size but no consensus has yet been reached on which method should be used in LCS. The 2 largest randomized screening trials have a different approach; NLST uses manual diameter and the NELSON trial uses volume and diameter^\[^[@B5]^,^[@B8]^\]^.

Solid nodules
-------------

Both manual (the largest or the 2 largest orthogonal dimensions) and volumetric measurement of lung nodules can be used in solid nodules. As reasonable doubts arise on the accuracy of manual measurements, in relation to the significant intra- and interobserver variability^\[^[@B39]^,^[@B40]^\]^, some authors suggest that volumetric analysis is a more accurate tool^\[^[@B41]^,^[@B42]^\]^. In the NELSON trial (in which solid nodules were measured by volumetric software with the exception of pleural-attached nodules), semi-automated measurements were not reproducible in 11% of solid nodules and, thus, may cause errors in the assessment of nodule growth^\[^[@B43]^\]^.

Various CT parameters can affect the volumetric analysis of lung nodules^\[^[@B44]^\]^. Among these, the slice thickness is the most important. Winer-Muram et al.^\[^[@B45]^\]^ showed an average percentage difference of 20% in volumetric measurements between thin and thick sections (36% for the smallest tumors). Nietert et al.^\[^[@B46]^\]^ showed that for assessing growth in pulmonary nodules, slice thicknesses ≥2.5 mm are essentially inadequate for 1-mm changes in nodule diameter^\[^[@B46]^\]^.

Size and shape can also influence the precision and accuracy of volumetric measurements. Lung nodule volume estimation error increases with decreasing nodule size^\[^[@B47]^\]^. Yankelevitz et al.^\[^[@B49]^\]^ studied nodule shape and found that volume measurements showed larger measurement error for elongated shapes (0.9--2.8%) than for spherical shapes (0.7--1.43%). Similar findings were reported by Marten et al.^\[^[@B50]^\]^. Moreover, juxtapleural and juxtavascular nodules can be segmented less accurately and sometimes they require manual correction, leading to higher variability in nodule measurements.

Different software packages provide different results and different segmentation algorithms, within the same software, which can affect nodule segmentation^\[^[@B51]^,^[@B52]^\]^.

Subsolid nodules
----------------

The measurement of subsolid nodules is more complex than for solid nodules; moreover, the typical slow growth of such nodules makes a precise estimation of growth more difficult at follow-up. Even though some commercially available software provides specific volumetric algorithms for non-solid nodules, the segmentation is often poor and manual correction is often required. To date, there is less compelling data supporting the use of the volumetric approach for subsolid nodules^\[^[@B42]^,^[@B49]^,^[@B53]^,^[@B54]^\]^. In addition, a subsolid nodule stable in diameter but with an increasing solid component at follow-up is suspicious for malignancy. In this case, neither manual nor volumetric assessment is appropriate. To address this issue, de Hoop et al.^\[^[@B55]^\]^ introduced the estimation of nodule mass (calculated by multiplying nodule volume by mean nodule density) as a method for measuring change in non-solid nodules. They demonstrated that mass measurements can enable detection of growth earlier and are subject to less variability than volume or diameter measurements. However, measuring the mass of a nodule requires a manual assessment of the volume of the lesion, which increases both reporting time and observer variability.

Follow-up studies and nodule growth
-----------------------------------

The same CT scanning and reconstruction parameters should be used at LDCT follow-up studies. When nodule size is determined volumetrically, the same software version and segmentation algorithm is recommended at follow-up examinations to avoid measurement inaccuracy^\[^[@B51]^,^[@B52]^,^[@B56]^\]^.

The definition of nodule growth in LCS is not widely accepted. In the I-ELCAP study, the definition of nodule growth was related to mean nodule diameter (defined as the mean of the longest diameter and its perpendicular diameter): ≥50% increase in mean diameter for nodules \<5 mm, ≥30% for nodules 5--9 mm and ≥20% for nodules larger than 10 mm^\[^[@B6]^\]^. The definition of growth in the NLST trial was an increase in nodule diameter ≥10%^\[^[@B5]^\]^. In the NELSON study, nodule growth (for solid nodules) was defined as a ≥25% change in volume after at least a 3-month interval^\[^[@B8]^\]^. Recently, the National Comprehensive Cancer Network defined nodule growth as an increase in mean diameter of 2 mm or more for nodules ≤15 mm (or in the solid portion of a part-solid nodule) or an increase of 15% in mean diameter for nodules \>15 mm^\[^[@B2]^\]^.

The estimation of nodule growth rate between 2 or more LDCT scans can be calculated by the doubling time (DT). The DT is defined as the time, expressed in days, for a nodule to double its volume. DT can be obtained from the maximum axial diameter: from the area or by volumetric analysis where *D*~t~ is the interval between 2 CT scans, *D*~1~ is the tumor diameter at the initial CT, *D*~2~ is the tumor diameter at the second CT, *A*~1~ is the tumor area at the initial CT, *A*~2~ is the tumor area at the second CT, *V*~1~ is the tumor volume at the initial CT, *V*~2~ is the tumor volume at the second CT. The DT calculation based on diameter estimates assumes uniform growth in 3 dimensions. Because nodules do not necessarily grow uniformly in all dimensions, volumetric determinations should theoretically provide more accurate information.

Regardless of diameter or volume assessment, DT is based on an exponential growth model. However, Lindell et al.^\[^[@B57]^\]^ showed that in a series of 18 screen-detected lung neoplasms, lung cancers are not limited to exponential growth. This has substantial meaning because studies and equations assuming exponential growth may potentially misrepresent an indeterminate nodule or the aggressiveness of a lung cancer.

Malignant nodules are generally rapidly growing lesions. Revel et al.^\[^[@B58]^\]^ reported that 98% of all cases of solid nodules with a DT of more than 500 days were non-malignant. The time of 500 days is generally accepted as the upper limit of the doubling time for malignant pulmonary lesions^\[^[@B59]^\]^, even though some lesions grow more slowly, especially for the spectrum of adenocarcinomas. In one LDCT study^\[^[@B60]^\]^, the DT was 988 ± 470 days for AAH, 567 ± 168 days for BAC, and 384 ± 212 days for mixed subtype of adenocarcinoma with BAC features. This implies that the widely accepted concept that 2-year stability is needed to differentiate malignant from benign nodules can be applied only to solid nodules but not to subsolid nodules that are mainly adenocarcinomas^\[^[@B61]^\]^.

The doubling times of benign nodules is generally less than 20 days or more than 450 days. However, the NELSON study has reported that significant growth may also occur in benign nodules: 58/68 (85%) nodules with a volume doubling time of \<400 days after 3 months were benign^\[^[@B62]^\]^.

LDCT: nodule management
=======================

The pulmonary nodule is a complex challenge in the interpretation of LDCT examinations. There are several nodule management protocols proposed by different LCS trials^\[^[@B5]^,^[@B63]^\]^, but currently it is difficult to determinate the most accurate protocol for LCS because of differing patient populations and study designs. Nodule size and growth rate have to be taken into consideration to assess which is the most appropriate work-up for each nodule. Most importantly, the approach to manage pulmonary nodules is multidisciplinary, with input from radiologists, pulmonologists, surgeons and nuclear medicine physicians. Therefore, we would not suggest a specific protocol for nodule management but rather the evaluation of the main variables that can influence the diagnostic algorithm in LCS.

Nodule size
-----------

Nodule size is one of the most important characteristics, as good evidence exists for a strong correlation between size and risk of malignancy^\[^[@B64]^,^[@B65]^\]^. In a meta-analysis of 8 large LDCT screening trials, the prevalence of malignancy depended on nodule size, ranging from 0% to 1% for nodules ≤5 mm, from 6% to 28% for those between 5 and 10 mm, and from 64% to 82% for nodules ≥20mm^\[^[@B63]^\]^.

To reduce the number of false-positive results in LCS trials, there is a broad consensus on considering an LDCT scan negative when lung nodule diameter is smaller than 4 mm^\[^[@B5]^\]^ or 5 mm^\[^[@B6]^,^[@B63]^\]^ or when volume is smaller than 50 mm[@B3] (diameter 4.6 mm)^\[^[@B8]^\]^. In this case, the participants received a repeat LDCT scan at a 1-year interval. Currently, if a nodule size at baseline or a new nodule at repeat scan is larger than such measurements, it is considered a positive result and further tests, according to nodule size and attenuation, are recommended.

In cases of a new nodule at repeat LDCT scan, size is the discriminant factor for its management. If it is \<5 mm (or \<4 mm or \<50 mm^3^), follow-up at a 1-year interval is suggested. If it is between 5 mm and 8--10 mm, an LDCT follow-up at 3 or 6 months is generally suggested. If nodule size is larger than 8--10 mm, LDCT follow-up at 1 or 3 months (with or without antibiotics), or positron emission tomography (PET) and/or biopsy should be considered, according to nodule attenuation.

If a nodule was present at the baseline scan and no growth is assessed at annual repeat LDCT scan, follow-up at 1 year is recommended by all screening protocols. The concept of 2-year stability at follow-up CT, as an indicator of the benign nature of a nodule, should be limited to solid nodules^\[^[@B61]^,^[@B66]^\]^.

Growth rate
-----------

The increase in the volume of a nodule over time is used as a method to differentiate benign from malignant nodules. If a nodule has grown, the size and the speed of growth should be considered to define its management. A very rapid growth rate (doubling time less than 1 month) is more suggestive of a benign lesion and, in this case, a course of antibiotics followed by CT 1 month later can be performed. If the nodule doubling time is less than 400 days, short LDCT follow-up (e.g. at 3 months) or PET or biopsy can be performed (according to nodule size); when the doubling time is 400--600 days, a follow-up scan can be obtained at 6 months or 1 year after^\[^[@B8]^\]^. If the doubling time is more than 600 days, repeat LDCT scan at 1 year can be suggested.

Subsolid nodules
----------------

Formal management guidelines for subsolid nodules have not yet been issued but interim management guidelines have recently been proposed by Godoy and Naidich^\[^[@B66]^\]^. As previously stated, non-solid nodules grow slowly but, at the same time, have a high malignancy rate ([Fig. 2](#F2){ref-type="fig"}). This implies that a minimum follow-up of 3 years is required for non-solid nodules to differentiate malignant from benign nodules and that any change in size or the development of a solid component is suspicious for malignancy^\[^[@B66]^\]^. Close follow-up is justified when a non-solid nodule is ≤10 mm^\[^[@B68]^\]^. When a non-solid nodule increases in size or if a solid component develops, PET and/or CT-guided biopsy or surgical biopsy should be performed. Many benign diseases, such as inflammatory disease or fibrosis, can also manifest as non-solid nodules.

Role of PET in LCS
------------------

PET scan using \[[@B18]F\]fluorodeoxyglucose can discriminate between malignant and benign pulmonary nodules^\[^[@B71]^,^[@B72]^\]^. Veronesi et al.^\[^[@B73]^\]^ found that the diagnostic sensitivity of PET/CT at baseline was 88% for solid nodules \>8 mm, but increased to 100% for solid nodules \>10 mm. However, in LCS, the value of PET is still unclear. Most screen-detected lung nodules are small and unfortunately the accuracy of PET for the assessment of small lesions is limited by the resolution power of scanners. Therefore, for nodules ≤8 mm PET scan should not be considered for nodule characterization^\[^[@B74]^,^[@B75]^\]^. Regardless of nodule size, however, PET has a lower sensitivity for slow-growing lesions, such as BACs and carcinoid tumors^\[^[@B74]^\]^. As most BACs are depicted as non-solid nodules, the role of PET imaging for assessing non-solid nodules remains to be established.

Invasive procedures and complications
-------------------------------------

Histologic samples of lung nodules can be obtained by CT-guided biopsy, bronchoscopic biopsy or wedge resection. Invasive procedures in LCS ranged from 10% to 43% according to different study designs^\[^[@B1]^,^[@B7]^,^[@B78]^\]^. Recently, the number of invasive procedures recommended for suspicious nodules in 4782 high-risk smokers was assessed^\[^[@B82]^\]^. The investigators showed that 104 of 124 biopsies (84%) were correctly indicated (true-positive recommendation) for malignancy. The only study reporting on complications resulting from LDCT screening is the NLST. In this study, the frequency of major complications occurring during the diagnostic evaluation was 33 per 10,000 individuals screened by LDCT.

Conclusions
===========

The NLST has demonstrated that the screening of high-risk populations with the use of LDCT reduces lung cancer mortality^\[^[@B1]^\]^. Reporting LDCT may appear unproblematic but radiologists involved in LCS should be aware that the interpretation of low-dose CT scans is not as easy as it may initially seem. Several considerations such as different nodule detection, tools and measurement assessments should be taken into account in order to avoid false-negative diagnoses as well as unnecessary follow-up examinations. Moreover, knowledge of the significance of different nodule types is essential, as different nodules require different approaches for their detection, measurement and management.

The management of pulmonary nodules in asymptomatic high-risk populations is a challenge and can differ significantly from clinical practice. Therefore, the experience of radiologists is crucial. Quality control in the interpretation of low-dose CT images and a multidisciplinary approach to manage positive results are decisive. CT scans should be interpreted by radiologists who have undergone specific training.

This paper is available online at <http://www.cancerimaging.org>. In the event of a change in the URL address, please use the DOI provided to locate the paper.

[^1]: NA, not available.

[^2]: ^a^Depending on the CT scanner and the participant's body habitus.

[^3]: ^b^Depending on the CT scanner adjusted to achieve the volume CT dose index given.
